ZYBT
Zhengye Biotechnology Holding Limited
Price Chart
Latest Quote
$0.83
| Previous Close | $0.83 |
| Open | $0.82 |
| Day High | $0.84 |
| Day Low | $0.82 |
| Volume | 7,677 |
Stock Information
| Shares Outstanding | 47.39M |
| Total Debt | $11.10M |
| Cash Equivalents | $7.67M |
| Revenue | $17.20M |
| Net Income | $-10.32M |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| Market Cap | $39.36M |
| EPS (TTM) | $-0.22 |
| Exchange | NCM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $119.39M |
| Sales | $17.20M |
| Income | $-10.32M |
| Book/sh | $0.91 |
| Cash/sh | $1.09 |
| Employees | 269 |
Financial Ratios
| Quick Ratio | 0.58 |
| Current Ratio | 1.14 |
| Debt/Eq | 24.48 |
Returns & Margins
| ROA | -9.48% |
| ROE | -25.17% |
| Gross Margin | 20.51% |
| Operating Margin | -77.04% |
| Profit Margin | -59.97% |
Ownership
| Insider Ownership | 16.16% |
| Institutional Ownership | 1.10% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| P/S | 0.34 |
| P/B | 0.91 |
Analyst Data
| Recommendation | none |
Technical Indicators
| SMA20 | $0.89 |
| SMA50 | $0.92 |
| SMA200 | $2.36 |
| RSI | 31.84 |
| ATR | 0.0559 |
| Shares Float | 6.26M |
| Short Float | 0.07% |
| Short Ratio | 0.53 |
| Rel Volume | 0.26 |
Performance History
| Week | -2.29% |
| Month | -15.69% |
| Quarter | +10.73% |
| 6 Months | -61.55% |
| YTD | -26.50% |
| Year | -87.08% |
| 10 Years | -82.91% |
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $0.83 | 7,677 |
| 2026-06-04 | $0.83 | 4,200 |
| 2026-06-03 | $0.80 | 5,700 |
| 2026-06-02 | $0.79 | 12,200 |
| 2026-06-01 | $0.85 | 8,900 |
| 2026-05-29 | $0.85 | 6,200 |
| 2026-05-28 | $0.81 | 3,000 |
| 2026-05-27 | $0.87 | 1,800 |
| 2026-05-26 | $0.86 | 2,700 |
| 2026-05-22 | $0.87 | 9,200 |
| 2026-05-21 | $0.87 | 24,000 |
| 2026-05-20 | $0.89 | 5,600 |
| 2026-05-19 | $0.87 | 11,300 |
| 2026-05-18 | $0.92 | 1,500 |
| 2026-05-15 | $0.95 | 4,400 |
| 2026-05-14 | $0.95 | 18,400 |
| 2026-05-13 | $0.96 | 17,100 |
| 2026-05-12 | $1.01 | 14,800 |
| 2026-05-11 | $1.00 | 431,700 |
| 2026-05-08 | $0.95 | 6,200 |
| 2026-05-07 | $0.98 | 29,800 |
| 2026-05-06 | $0.99 | 604,600 |
About Zhengye Biotechnology Holding Limited
Zhengye Biotechnology Holding Limited engages in the research, development, manufacture, and sale of veterinary vaccines for livestock in the People's Republic of China. The company offers vaccines for swine, cattle, goats, sheep, poultry, and dogs, as well as monovalent vaccine, polyvalent vaccine, combined vaccine, and combined and polyvalent vaccine. It also develops vaccines for household animals, including rabies vaccine and Strain Flury LEP for dogs. In addition, the company exports its products to Vietnam, Pakistan, and Egypt. It serves direct-end customers, including livestock farmers and local governments; and domestic distributors and exporting distributors. The company was incorporated in 2004 and is based in Jilin, China. Zhengye Biotechnology Holding Limited operates as a subsidiary of Securingium Holding Limited.
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $13,678,956 | $14,058,742 | $13,922,978 | $16,621,559 |
| Cost Of Revenue | $13,678,956 | $14,058,742 | $13,922,978 | $16,621,559 |
| Total Revenue | $17,208,986 | $27,560,524 | $31,301,447 | $38,491,651 |
| Operating Revenue | $15,177,100 | $25,628,909 | $30,221,541 | $37,265,776 |
| Expenses | ||||
| Interest Expense | $502,832 | $597,927 | $654,125 | $419,865 |
| Total Expenses | $27,303,193 | $25,020,926 | $24,256,030 | $28,717,630 |
| Other Income Expense | $-46,586 | $152,920 | $34,607 | $81,340 |
| Other Non Operating Income Expenses | $-19,226 | $21,592 | $34,607 | $81,340 |
| Net Non Operating Interest Income Expense | $-488,635 | $-563,764 | $-607,983 | $-403,005 |
| Interest Expense Non Operating | $502,832 | $597,927 | $654,125 | $419,865 |
| Operating Expense | $13,624,236 | $10,962,184 | $10,333,052 | $12,096,070 |
| Other Operating Expenses | $-333,052 | $-108,405 | $-392,357 | $-37,712 |
| Selling And Marketing Expense | $6,495,112 | $6,103,347 | $6,025,556 | $5,111,880 |
| General And Administrative Expense | $4,585,533 | $3,338,657 | $3,489,063 | $3,596,876 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $-10,320,481 | $1,672,804 | $4,652,232 | $6,911,723 |
| Net Interest Income | $-488,635 | $-563,764 | $-607,983 | $-403,005 |
| Interest Income | $14,198 | $34,163 | $46,142 | $16,860 |
| Normalized Income | $-10,299,961 | $1,549,907 | $4,652,232 | $6,911,723 |
| Net Income From Continuing And Discontinued Operation | $-10,320,481 | $1,672,804 | $4,652,232 | $6,911,723 |
| Total Operating Income As Reported | $-10,427,259 | $2,431,193 | $6,653,061 | $9,736,309 |
| Net Income Common Stockholders | $-10,320,481 | $1,672,804 | $4,652,232 | $6,911,723 |
| Net Income | $-10,320,481 | $1,672,804 | $4,652,232 | $6,911,723 |
| Net Income Including Noncontrolling Interests | $-12,270,287 | $1,992,103 | $5,547,274 | $8,243,785 |
| Net Income Continuous Operations | $-12,270,287 | $1,992,103 | $5,547,274 | $8,243,785 |
| Pretax Income | $-10,629,427 | $2,128,755 | $6,472,041 | $9,452,357 |
| Interest Income Non Operating | $14,198 | $34,163 | $46,142 | $16,860 |
| Operating Income | $-10,094,207 | $2,539,598 | $7,045,417 | $9,774,021 |
| Gross Profit | $3,530,029 | $13,501,782 | $17,378,470 | $21,870,091 |
| Special Income Charges | - | - | $-1,486,017 | $-143,159 |
| Per Share | ||||
| Diluted EPS | - | $0.04 | $0.10 | $0.15 |
| Basic EPS | - | $0.04 | $0.10 | $0.15 |
| Other | ||||
| Tax Effect Of Unusual Items | $-6,840 | $8,430 | $0 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $-6,260,704 | $6,168,863 | $10,662,555 | $12,652,587 |
| Total Unusual Items | $-27,360 | $131,328 | $-1,486,017 | $-143,159 |
| Total Unusual Items Excluding Goodwill | $-27,360 | $131,328 | $-1,486,017 | $-143,159 |
| Reconciled Depreciation | $3,838,532 | $3,573,510 | $3,536,389 | $2,780,366 |
| EBITDA (Bullshit earnings) | $-6,288,064 | $6,300,191 | $10,662,555 | $12,652,587 |
| EBIT | $-10,126,595 | $2,726,681 | $7,126,166 | $9,872,221 |
| Diluted NI Availto Com Stockholders | $-10,320,481 | $1,672,804 | $4,652,232 | $6,911,723 |
| Minority Interests | $1,949,805 | $-319,298 | $-895,041 | $-1,332,061 |
| Tax Provision | $1,640,860 | $136,652 | $924,767 | $1,208,572 |
| Gain On Sale Of Security | $-27,360 | $131,328 | - | - |
| Provision For Doubtful Accounts | $212,668 | $-263,543 | $-549,270 | $1,439,727 |
| Research And Development | $2,663,975 | $1,892,128 | $1,760,060 | $1,985,300 |
| Selling General And Administration | $11,080,645 | $9,442,004 | $9,514,619 | $8,708,757 |
| Other Gand A | $4,585,533 | $3,338,657 | $3,489,063 | $3,596,876 |
| Diluted Average Shares | - | $6,975,520 | $6,975,520 | $6,975,520 |
| Basic Average Shares | - | $6,975,520 | $6,753,683 | $6,753,683 |
| Write Off | - | - | $1,486,017 | $143,159 |
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $28,852,359 | $38,626,232 | $36,731,295 | $39,722,850 |
| Total Assets | $64,550,630 | $72,947,187 | $73,929,336 | $76,855,523 |
| Total Non Current Assets | $44,227,339 | $46,686,631 | $45,942,144 | $45,161,127 |
| Non Current Prepaid Assets | $1,037,313 | $2,765,281 | $961,888 | $330,390 |
| Non Current Deferred Assets | $0 | $2,815,712 | $2,427,052 | - |
| Non Current Deferred Taxes Assets | $0 | $1,625,479 | $1,761,983 | - |
| Goodwill And Other Intangible Assets | $8,098,111 | $3,368,975 | $3,620,983 | $4,126,625 |
| Other Intangible Assets | $8,098,111 | $3,368,975 | $3,620,983 | $4,126,625 |
| Current Assets | $20,323,291 | $26,260,555 | $27,987,192 | $31,694,396 |
| Other Current Assets | $1,001,819 | $2,869,397 | - | - |
| Restricted Cash | $296 | $296 | $1,791,413 | $0 |
| Prepaid Assets | $3,120,665 | $-776,432 | $459,943 | $359,821 |
| Inventory | $5,792,330 | $8,610,261 | $8,622,092 | $8,196,755 |
| Receivables | $2,733,780 | $12,593,726 | $14,703,551 | $19,854,474 |
| Notes Receivable | $0 | $3,784,847 | $3,433,308 | $4,537,173 |
| Accounts Receivable | $2,733,780 | $8,808,879 | $10,968,543 | $15,217,918 |
| Allowance For Doubtful Accounts Receivable | $-2,667,081 | $-2,495,526 | $-2,753,154 | $-3,161,483 |
| Gross Accounts Receivable | $5,400,861 | $11,304,406 | $13,721,697 | $18,379,401 |
| Cash Cash Equivalents And Short Term Investments | $7,674,401 | $2,963,308 | $2,410,193 | $1,441,353 |
| Cash And Cash Equivalents | $7,443,690 | $2,751,379 | $2,229,173 | $1,441,353 |
| Cash Financial | $7,443,690 | $2,751,379 | $2,229,173 | $1,441,353 |
| Other Receivables | - | $388,364 | $192,555 | $99,383 |
| Current Deferred Assets | - | - | $2,427,052 | $1,841,992 |
| Current Deferred Taxes Assets | - | - | $1,761,983 | $1,841,992 |
| Debt | ||||
| Net Debt | $3,596,433 | $10,031,353 | $11,058,905 | $8,153,867 |
| Total Debt | $11,104,160 | $12,782,732 | $13,288,078 | $9,595,220 |
| Long Term Debt And Capital Lease Obligation | $1,357,203 | $709,881 | $1,477,439 | $1,477,439 |
| Long Term Debt | $1,308,842 | $709,881 | $1,477,439 | $1,477,439 |
| Current Debt And Capital Lease Obligation | $9,746,957 | $12,072,851 | $11,810,639 | $8,117,781 |
| Current Debt | $9,731,280 | $12,072,851 | $11,810,639 | $8,117,781 |
| Other Current Borrowings | $103,524 | $1,063,342 | $11,810,639 | $8,117,781 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $19,189,996 | $20,809,412 | $23,753,789 | $24,077,820 |
| Total Non Current Liabilities Net Minority Interest | $1,372,584 | $709,881 | $1,535,561 | $1,564,695 |
| Non Current Deferred Liabilities | $15,381 | $0 | - | - |
| Non Current Deferred Taxes Liabilities | $15,381 | $0 | - | - |
| Current Liabilities | $17,817,412 | $20,099,531 | $22,218,229 | $22,513,125 |
| Other Current Liabilities | $58,713 | $82,228 | $124,377 | $131,032 |
| Current Deferred Liabilities | $713,874 | $947,395 | $589,349 | $695,239 |
| Payables And Accrued Expenses | $7,297,869 | $6,997,057 | $9,693,864 | $13,569,073 |
| Payables | $7,224,367 | $6,982,416 | $9,692,385 | $13,567,594 |
| Other Payable | $368,842 | $301,847 | $285,579 | $364,997 |
| Total Tax Payable | $346,806 | $305,544 | $339,412 | $1,478,326 |
| Accounts Payable | $6,508,718 | $6,353,432 | $6,752,592 | $11,724,270 |
| Tradeand Other Payables Non Current | - | $0 | $58,121 | $87,256 |
| Dividends Payable | - | $0 | $2,314,802 | $0 |
| Equity | ||||
| Common Stock Equity | $36,950,470 | $41,995,208 | $40,352,278 | $43,849,475 |
| Total Equity Gross Minority Interest | $45,360,633 | $52,137,775 | $50,175,547 | $52,777,703 |
| Stockholders Equity | $36,950,470 | $41,995,208 | $40,352,278 | $43,849,475 |
| Gains Losses Not Affecting Retained Earnings | $4,543,384 | $4,828,667 | $4,630,640 | $4,076,637 |
| Other Equity Adjustments | $4,543,384 | $4,828,667 | $4,630,640 | $4,076,637 |
| Retained Earnings | $-3,199,343 | $7,121,138 | $5,676,235 | $9,727,435 |
| Other | ||||
| Ordinary Shares Number | $7,008,796 | $6,975,520 | $6,975,520 | $6,975,520 |
| Share Issued | $7,008,796 | $6,975,520 | $6,975,520 | $6,975,520 |
| Tangible Book Value | $28,852,359 | $38,626,232 | $36,731,295 | $39,722,850 |
| Invested Capital | $47,990,593 | $54,777,940 | $53,640,356 | $53,444,695 |
| Working Capital | $2,505,879 | $6,161,024 | $5,768,963 | $9,181,271 |
| Capital Lease Obligations | $64,037 | $0 | - | - |
| Total Capitalization | $38,259,313 | $42,705,088 | $41,829,717 | $45,326,914 |
| Minority Interest | $8,410,163 | $10,142,568 | $9,823,269 | $8,928,228 |
| Additional Paid In Capital | $35,605,247 | $30,044,219 | $30,044,219 | $30,044,219 |
| Capital Stock | $1,183 | $1,183 | $1,183 | $1,183 |
| Common Stock | $1,183 | $1,183 | $1,183 | $1,183 |
| Long Term Capital Lease Obligation | $48,361 | $0 | - | - |
| Current Deferred Revenue | $713,874 | $544,981 | $589,349 | $695,239 |
| Current Capital Lease Obligation | $15,677 | $0 | - | - |
| Line Of Credit | $9,627,756 | $11,009,509 | $11,810,639 | - |
| Current Accrued Expenses | $73,502 | $14,641 | $1,479 | $1,479 |
| Dueto Related Parties Current | $0 | $21,592 | $0 | - |
| Net PPE | $35,091,914 | $37,736,663 | $38,932,221 | $40,704,112 |
| Accumulated Depreciation | $-19,488,442 | $-16,497,774 | $-13,694,929 | $-10,858,512 |
| Gross PPE | $54,580,356 | $54,234,437 | $52,627,149 | $51,562,624 |
| Construction In Progress | $90,214 | $1,442,241 | $1,126,344 | $12,136,593 |
| Other Properties | $21,892,275 | $21,926,586 | $21,852,492 | $21,219,220 |
| Machinery Furniture Equipment | $485,085 | $484,937 | $484,937 | $491,001 |
| Buildings And Improvements | $32,112,782 | $30,380,673 | $29,163,376 | $17,715,811 |
| Properties | $0 | $0 | $0 | $0 |
| Finished Goods | $2,002,751 | $2,623,157 | $2,197,524 | $2,068,119 |
| Work In Process | $2,616,058 | $4,888,416 | $4,965,171 | $5,012,645 |
| Raw Materials | $1,173,521 | $1,098,688 | $1,459,396 | $1,612,908 |
| Duefrom Related Parties Current | $0 | $0 | $109,144 | $0 |
| Other Short Term Investments | $230,711 | $211,929 | $181,020 | $0 |
| Land And Improvements | - | - | $1,901,889 | $1,901,889 |
| Inventories Adjustments Allowances | - | - | $-1,979,828 | $-496,916 |
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $103,968 | $1,962,968 | $5,410,474 | $-1,477,883 |
| Operating Activities | ||||
| Operating Cash Flow | $1,971,841 | $6,070,367 | $7,126,018 | $2,563,704 |
| Cash Flow From Continuing Operating Activities | $1,971,841 | $6,070,367 | $7,126,018 | $2,563,704 |
| Operating Gains Losses | $46,142 | $-74,685 | $27,656 | - |
| Investing Activities | ||||
| Capital Expenditure | $-1,867,873 | $-4,107,399 | $-1,715,545 | $-4,041,587 |
| Investing Cash Flow | $-1,867,873 | $-4,091,427 | $-1,739,947 | $-4,041,587 |
| Cash Flow From Continuing Investing Activities | $-1,867,873 | $-4,091,427 | $-1,739,947 | $-4,041,587 |
| Financing Activities | ||||
| Issuance Of Capital Stock | $6,371,179 | $0 | $0 | - |
| Financing Cash Flow | $4,778,384 | $-3,272,698 | $-2,806,838 | $1,989,884 |
| Cash Flow From Continuing Financing Activities | $4,778,384 | $-3,272,698 | $-2,806,838 | $1,989,884 |
| Net Other Financing Charges | $195,809 | $-498,100 | $-665,069 | - |
| Cash Dividends Paid | $0 | $-2,369,670 | $-5,834,627 | $-3,168,582 |
| Common Stock Dividend Paid | $0 | $-2,369,670 | $-5,834,627 | $-3,168,582 |
| Net Common Stock Issuance | $6,371,179 | $0 | $0 | - |
| Common Stock Issuance | $6,371,179 | $0 | $0 | - |
| Other | ||||
| Repayment Of Debt | $-12,210,243 | $-13,733,233 | $-8,117,781 | $-9,608,826 |
| Issuance Of Debt | $10,421,639 | $13,328,305 | $11,810,639 | $14,767,292 |
| Interest Paid Supplemental Data | $496,325 | $589,349 | $654,125 | $419,865 |
| Income Tax Paid Supplemental Data | $0 | $17,155 | $1,550,793 | $1,254,270 |
| End Cash Position | $7,443,986 | $2,751,675 | $4,020,586 | $1,441,353 |
| Beginning Cash Position | $2,751,675 | $4,020,586 | $1,441,353 | $929,352 |
| Effect Of Exchange Rate Changes | $-190,041 | $24,846 | $0 | $0 |
| Changes In Cash | $4,882,352 | $-1,293,757 | $2,579,233 | $512,001 |
| Net Issuance Payments Of Debt | $-1,788,603 | $-404,928 | $3,692,858 | $5,158,466 |
| Net Long Term Debt Issuance | $-1,788,603 | $-404,928 | $3,692,858 | $5,158,466 |
| Long Term Debt Payments | $-12,210,243 | $-13,733,233 | $-8,117,781 | $-9,608,826 |
| Long Term Debt Issuance | $10,421,639 | $13,328,305 | $11,810,639 | $14,767,292 |
| Net Investment Purchase And Sale | $0 | $0 | $-181,020 | $0 |
| Purchase Of Investment | $0 | $0 | $-181,020 | $0 |
| Net Intangibles Purchase And Sale | $-1,718,798 | $-2,097,993 | $-621,737 | $0 |
| Purchase Of Intangibles | $-1,718,798 | $-2,097,993 | $-621,737 | $0 |
| Net PPE Purchase And Sale | $-149,075 | $-1,993,434 | $-937,190 | $-4,041,587 |
| Sale Of PPE | $0 | $15,972 | $156,617 | $0 |
| Purchase Of PPE | $-149,075 | $-2,009,406 | $-1,093,808 | $-4,041,587 |
| Change In Working Capital | $6,629,546 | $-144,490 | $-2,998,802 | $-9,849,446 |
| Change In Other Working Capital | $187,379 | $-59,157 | $-105,743 | $46,882 |
| Change In Other Current Liabilities | $-15,972 | $0 | $0 | $-30,170 |
| Change In Payables And Accrued Expense | $-394,280 | $247,275 | $-6,521,141 | $-961,297 |
| Change In Accrued Expense | $61,671 | $399,012 | $-86,073 | $30,614 |
| Change In Payable | $-455,950 | $-151,737 | $-6,435,068 | $-991,910 |
| Change In Account Payable | $-497,212 | $-59,748 | $-5,266,871 | $-1,430,557 |
| Change In Tax Payable | $41,262 | $-33,867 | $-1,139,063 | $471,923 |
| Change In Income Tax Payable | $41,262 | $-33,867 | $-1,139,063 | $471,923 |
| Change In Prepaid Assets | $-3,154,088 | $-1,325,111 | $-174,808 | $-106,038 |
| Change In Inventory | $924,620 | $-869,900 | $-1,908,100 | $-1,822,766 |
| Change In Receivables | $9,081,888 | $1,862,401 | $5,710,990 | $-7,006,226 |
| Changes In Account Receivables | $5,872,635 | $2,417,291 | $4,591,153 | $-3,656,477 |
| Unrealized Gain Loss On Investment Securities | $-18,782 | $-30,909 | $0 | $0 |
| Provisionand Write Offof Assets | $212,668 | $-263,543 | $-549,270 | $1,439,727 |
| Asset Impairment Charge | $1,893,163 | $881,731 | $1,482,763 | $143,159 |
| Deferred Tax | $1,640,860 | $136,652 | $80,009 | $-193,886 |
| Deferred Income Tax | $1,640,860 | $136,652 | $80,009 | $-193,886 |
| Depreciation Amortization Depletion | $3,838,532 | $3,573,510 | $3,536,389 | $2,780,366 |
| Depreciation And Amortization | $3,838,532 | $3,573,510 | $3,536,389 | $2,780,366 |
| Depreciation | $3,838,532 | $3,573,510 | $3,536,389 | - |
| Net Foreign Currency Exchange Gain Loss | $46,142 | $-100,419 | $0 | $0 |
| Gain Loss On Sale Of PPE | $0 | $25,733 | $27,656 | $0 |
| Net Income From Continuing Operations | $-12,270,287 | $1,992,103 | $5,547,274 | $8,243,785 |
| Other Non Cash Items | - | - | - | - |